[
  {
    "ts": null,
    "headline": "5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine",
    "summary": "Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals. These five stocks deliver that combination, each offering distinct advantages for compounding wealth over time. #5: Procter & Gamble (PG): The Steady Compounder Procter & Gamble earns ... 5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine",
    "url": "https://finnhub.io/api/news?id=fc561247fd62bd4b94117719b45b5f666483ccb5ebfcb46806cb9e2cea1d01e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765650407,
      "headline": "5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine",
      "id": 137792123,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals. These five stocks deliver that combination, each offering distinct advantages for compounding wealth over time. #5: Procter & Gamble (PG): The Steady Compounder Procter & Gamble earns ... 5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine",
      "url": "https://finnhub.io/api/news?id=fc561247fd62bd4b94117719b45b5f666483ccb5ebfcb46806cb9e2cea1d01e3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The Right Long-Term Strategy",
    "summary": "Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more on LLY stock here.",
    "url": "https://finnhub.io/api/news?id=7cbe803f884a8945aad6b83c6a9a2ce67e0afb8f38f6abe0065fab9acd887ad6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765600404,
      "headline": "Eli Lilly: The Right Long-Term Strategy",
      "id": 137774561,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1874681159/image_1874681159.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more on LLY stock here.",
      "url": "https://finnhub.io/api/news?id=7cbe803f884a8945aad6b83c6a9a2ce67e0afb8f38f6abe0065fab9acd887ad6"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, representing a significant unmet need not addressed by prev",
    "url": "https://finnhub.io/api/news?id=8f3e653324682f43aa50bc809829ef353188bd4527a81110a6b1a1e4fb36a44d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765589100,
      "headline": "U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*",
      "id": 137792124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, representing a significant unmet need not addressed by prev",
      "url": "https://finnhub.io/api/news?id=8f3e653324682f43aa50bc809829ef353188bd4527a81110a6b1a1e4fb36a44d"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains Johnson & Johnson (JNJ) Equal-Weight Recommendation",
    "summary": "Morgan Stanley Maintains Johnson & Johnson (JNJ) Equal-Weight Recommendation",
    "url": "https://finnhub.io/api/news?id=5df089bd6e6a8e3b44cc5c5719ff8a86672e0111f31ddd25f71b087b46a794ce",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765584449,
      "headline": "Morgan Stanley Maintains Johnson & Johnson (JNJ) Equal-Weight Recommendation",
      "id": 137772401,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5df089bd6e6a8e3b44cc5c5719ff8a86672e0111f31ddd25f71b087b46a794ce"
    }
  }
]